TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic ...
Agence France-Presse

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO ® (vedolizumab) can offer the possibility of clinical remission for ...
Healthline

Can you cure microscopic colitis or will it return?

Microscopic colitis is a lifelong condition that causes symptoms such as diarrhea and abdominal pain. It is a type of inflammatory bowel disease (IBD). While there is no cure for microscopic colitis, ...
Yahoo

She Found a Natural Ulcerative Colitis Cure That Really Works

Add Yahoo as a preferred source to see more of our stories on Google. “Debilitating digestive issues dominated my life because I couldn’t go longer than a half hour without going to the bathroom,” ...
News-Medical.Net on MSN

Blood markers can indicate people at risk of developing ulcerative colitis

Researchers at örebro University have identified blood markers that can indicate who is at risk of developing ulcerative ...
WebMD

Infusion Therapy for Ulcerative Colitis

What Is Infusion for Ulcerative Colitis? If your doctor has recommended infusion therapy, this is probably because standard treatment hasn’t helped relieve symptoms caused by moderate-to-severe ...
Healio

Clinicians ‘increasingly comfortable’ using mirikizumab earlier in ulcerative colitis

More than a quarter of patients with ulcerative colitis do not receive prior advanced therapy before initiating mirikizumab, ...